Do analysts prefer NTRB or AMRN?

Amarin has a consensus target price of $13.00, indicating a potential downside of 5.80%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Amarin 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33

Which has higher earnings and valuation, NTRB or AMRN?

Nutriband has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nutriband $2.04M 41.49 -$8.23M -$0.53 N/A Amarin $213.65M 1.36 -$38.80M -$0.99 N/A

Is NTRB or AMRN more profitable?

Amarin has a net margin of -14.56% compared to Nutriband's net margin of -430.35%. Amarin's return on equity of -0.20% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -430.35% -109.07% -95.54% Amarin -14.56% -0.20% -0.14%

Does the media refer more to NTRB or AMRN?

In the previous week, Nutriband had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Nutriband and 2 mentions for Amarin. Nutriband's average media sentiment score of 0.96 beat Amarin's score of 0.54 indicating that Nutriband is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nutriband 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZNTL or NTRB?

In the previous week, Nutriband had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 4 mentions for Nutriband and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.07 beat Nutriband's score of 0.96 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nutriband 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NTRB or ACB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is NTRB or ACB more profitable?

Aurora Cannabis has a net margin of -32.26% compared to Nutriband's net margin of -430.35%. Aurora Cannabis' return on equity of 4.37% beat Nutriband's return on equity. Company Net Margins Return on Equity Return on Assets Nutriband -430.35% -109.07% -95.54% Aurora Cannabis -32.26% 4.37% 3.45%

Does the media refer more to NTRB or ACB?

In the previous week, Aurora Cannabis had 3 more articles in the media than Nutriband. MarketBeat recorded 7 mentions for Aurora Cannabis and 4 mentions for Nutriband. Nutriband's average media sentiment score of 0.96 beat Aurora Cannabis' score of 0.45 indicating that Nutriband is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nutriband 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CRDL or NTRB?

Cardiol Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 401.25%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media prefer CRDL or NTRB?

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 4 articles in the media. Nutriband's average media sentiment score of 0.96 beat Cardiol Therapeutics' score of 0.63 indicating that Nutriband is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nutriband 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NMRA or NTRB?

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 531.87%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than Nutriband. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 2 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.60 Nutriband 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Nutriband (NTRB) Competitors

$6.96 +0.88 (+14.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$6.90 -0.07 (-0.93%)

As of 09/11/2026 07:49 PM Eastern

Compare

NTRB vs. AMRN, ZNTL, ACB, CRDL, and NMRA

Should you buy Nutriband stock or one of its competitors? Nutriband's main competitors and comparable companies include Amarin (AMRN), Zentalis Pharmaceuticals (ZNTL), Aurora Cannabis (ACB), Cardiol Therapeutics (CRDL), and Neumora Therapeutics (NMRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Nutriband compare to Amarin?

Nutriband (NASDAQ:NTRB) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Nutriband had 2 more articles in the media than Amarin. MarketBeat recorded 4 mentions for Nutriband and 2 mentions for Amarin. Nutriband's average media sentiment score of 0.96 beat Amarin's score of 0.54 indicating that Nutriband is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nutriband	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

19.7% of Nutriband shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 52.2% of Nutriband shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Amarin has a consensus target price of $13.00, indicating a potential downside of 5.80%. Given Amarin's higher probable upside, analysts clearly believe Amarin is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Amarin has a net margin of -14.56% compared to Nutriband's net margin of -430.35%. Amarin's return on equity of -0.20% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Amarin	-14.56%	-0.20%	-0.14%

Nutriband has a beta of 2.03, meaning that its share price is 103% more volatile than the broader market. Comparatively, Amarin has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Nutriband has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Nutriband, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	41.49	-$8.23M	-$0.53	N/A
Amarin	$213.65M	1.36	-$38.80M	-$0.99	N/A

Summary

Nutriband beats Amarin on 9 of the 15 factors compared between the two stocks.

How does Nutriband compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Zentalis Pharmaceuticals currently has a consensus target price of $6.75, indicating a potential upside of 92.31%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Zentalis Pharmaceuticals is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Zentalis Pharmaceuticals' return on equity of -70.18% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Nutriband	-430.35%	-109.07%	-95.54%

19.7% of Nutriband shares are owned by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Comparatively, 52.2% of Nutriband shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nutriband has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Nutriband is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	3.73	-$137.06M	-$1.95	N/A
Nutriband	$2.04M	41.49	-$8.23M	-$0.53	N/A

Zentalis Pharmaceuticals has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, Nutriband has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market.

In the previous week, Nutriband had 1 more articles in the media than Zentalis Pharmaceuticals. MarketBeat recorded 4 mentions for Nutriband and 3 mentions for Zentalis Pharmaceuticals. Zentalis Pharmaceuticals' average media sentiment score of 1.07 beat Nutriband's score of 0.96 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nutriband	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zentalis Pharmaceuticals beats Nutriband on 9 of the 16 factors compared between the two stocks.

How does Nutriband compare to Aurora Cannabis?

Nutriband (NASDAQ:NTRB) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

In the previous week, Aurora Cannabis had 3 more articles in the media than Nutriband. MarketBeat recorded 7 mentions for Aurora Cannabis and 4 mentions for Nutriband. Nutriband's average media sentiment score of 0.96 beat Aurora Cannabis' score of 0.45 indicating that Nutriband is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nutriband	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurora Cannabis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.7% of Nutriband shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Nutriband has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Aurora Cannabis has a net margin of -32.26% compared to Nutriband's net margin of -430.35%. Aurora Cannabis' return on equity of 4.37% beat Nutriband's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nutriband	-430.35%	-109.07%	-95.54%
Aurora Cannabis	-32.26%	4.37%	3.45%

Nutriband has higher earnings, but lower revenue than Aurora Cannabis. Nutriband is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nutriband	$2.04M	41.49	-$8.23M	-$0.53	N/A
Aurora Cannabis	$247.82M	0.98	-$88.13M	-$1.41	N/A

Summary

Aurora Cannabis beats Nutriband on 10 of the 16 factors compared between the two stocks.

How does Nutriband compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Cardiol Therapeutics and Cardiol Therapeutics both had 4 articles in the media. Nutriband's average media sentiment score of 0.96 beat Cardiol Therapeutics' score of 0.63 indicating that Nutriband is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nutriband	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Nutriband has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market.

Nutriband has higher revenue and earnings than Cardiol Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A
Nutriband	$2.04M	41.49	-$8.23M	-$0.53	N/A

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cardiol Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 401.25%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cardiol Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cardiol Therapeutics has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-180.44%	-140.28%
Nutriband	-430.35%	-109.07%	-95.54%

Summary

Nutriband beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Nutriband compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Nutriband (NASDAQ:NTRB) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Neumora Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market. Comparatively, Nutriband has a beta of 2.03, indicating that its share price is 103% more volatile than the broader market.

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 26.9% of Neumora Therapeutics shares are held by company insiders. Comparatively, 52.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Neumora Therapeutics presently has a consensus target price of $6.57, suggesting a potential upside of 531.87%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Neumora Therapeutics is more favorable than Nutriband.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Nutriband	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Neumora Therapeutics has a net margin of 0.00% compared to Nutriband's net margin of -430.35%. Nutriband's return on equity of -109.07% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Nutriband	-430.35%	-109.07%	-95.54%

Nutriband has higher revenue and earnings than Neumora Therapeutics. Nutriband is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Nutriband	$2.04M	41.49	-$8.23M	-$0.53	N/A

In the previous week, Nutriband had 3 more articles in the media than Neumora Therapeutics. MarketBeat recorded 4 mentions for Nutriband and 1 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.87 beat Nutriband's score of 0.96 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Very Positive
Nutriband	Positive

Summary

Neumora Therapeutics beats Nutriband on 9 of the 16 factors compared between the two stocks.

Get Nutriband News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NTRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NTRB vs. The Competition

Export

Metric	Nutriband	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.60M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.71%
P/E Ratio	-13.13	799.75	274.94	25.33
Price / Sales	41.49	756.96	633.80	90.72
Price / Cash	N/A	14.86	28.42	34.96
Price / Book	12.65	10.39	10.33	6.21
Net Income	-$8.23M	$2.85B	$3.50B	$358.54M
7 Day Performance	16.58%	-3.61%	-3.32%	-2.35%
1 Month Performance	118.18%	0.72%	-0.53%	-3.23%
1 Year Performance	-2.66%	3.61%	23.51%	8.79%

Nutriband Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NTRB Nutriband	0.6653 of 5 stars	$6.96 +14.5%	N/A	-2.7%	$84.60M	$2.04M	N/A	10	Earnings Report
AMRN Amarin	0.9375 of 5 stars	$14.25 +4.5%	$13.00 -8.8%	-8.1%	$287.91M	$186.23M	N/A	360
ZNTL Zentalis Pharmaceuticals	3.4295 of 5 stars	$4.03 +1.0%	$6.75 +67.5%	+135.6%	$285.97M	N/A	N/A	160
ACB Aurora Cannabis	1.1864 of 5 stars	$3.87 -2.0%	N/A	-23.2%	$256.12M	$247.82M	N/A	1,028	Analyst Upgrade
CRDL Cardiol Therapeutics	2.8154 of 5 stars	$2.22 +0.9%	$10.00 +350.5%	+86.4%	$255.59M	N/A	N/A	20	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NTRB) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nutriband (NTRB) Competitors

NTRB vs. AMRN, ZNTL, ACB, CRDL, and NMRA

How does Nutriband compare to Amarin?

Summary

How does Nutriband compare to Zentalis Pharmaceuticals?

Summary

How does Nutriband compare to Aurora Cannabis?

Summary

How does Nutriband compare to Cardiol Therapeutics?

Summary

How does Nutriband compare to Neumora Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nutriband (NTRB) Competitors

NTRB vs. AMRN, ZNTL, ACB, CRDL, and NMRA

How does Nutriband compare to Amarin?

Does the media refer more to NTRB or AMRN?

Do institutionals and insiders believe in NTRB or AMRN?

Do analysts prefer NTRB or AMRN?

Is NTRB or AMRN more profitable?

Which has more volatility and risk, NTRB or AMRN?

Which has higher earnings and valuation, NTRB or AMRN?

Summary

How does Nutriband compare to Zentalis Pharmaceuticals?

Do analysts rate ZNTL or NTRB?

Is ZNTL or NTRB more profitable?

Do institutionals & insiders have more ownership in ZNTL or NTRB?

Which has better earnings & valuation, ZNTL or NTRB?

Which has more risk & volatility, ZNTL or NTRB?

Does the media refer more to ZNTL or NTRB?

Summary

How does Nutriband compare to Aurora Cannabis?

Does the media refer more to NTRB or ACB?

Do institutionals and insiders hold more shares of NTRB or ACB?

Which has more volatility and risk, NTRB or ACB?

Do analysts prefer NTRB or ACB?

Is NTRB or ACB more profitable?

Which has stronger valuation and earnings, NTRB or ACB?

Summary

How does Nutriband compare to Cardiol Therapeutics?

Does the media prefer CRDL or NTRB?

Which has more volatility & risk, CRDL or NTRB?

Which has preferable earnings and valuation, CRDL or NTRB?

Do institutionals and insiders have more ownership in CRDL or NTRB?

Do analysts recommend CRDL or NTRB?

Is CRDL or NTRB more profitable?

Summary

How does Nutriband compare to Neumora Therapeutics?

Which has more volatility and risk, NMRA or NTRB?

Do insiders & institutionals have more ownership in NMRA or NTRB?

Do analysts recommend NMRA or NTRB?

Is NMRA or NTRB more profitable?

Which has higher valuation & earnings, NMRA or NTRB?

Does the media favor NMRA or NTRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NTRB vs. The Competition

Nutriband Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools